FINE-REAL: Finerenone in Routine Clinical Practice

Study Overview

A prospective, non-interventional study evaluating real-world treatment patterns, safety outcomes, and healthcare utilization in CKD patients with Type 2 Diabetes treated with finerenone, a novel non-steroidal mineralocorticoid receptor antagonist.

Inclusion Criteria

• ✓Adults aged 18 years or older
• ✓Diagnosis of CKD with Type 2 Diabetes
• ✓Physician decision to initiate finerenone treatment
• ✓Currently on optimized RAS inhibitor therapy (ACEi or ARB)

Exclusion Criteria

• ✗Participation in an interventional clinical trial
• ✗Contraindications per local finerenone labeling
• ✗Known hypersensitivity to finerenone or excipients
• ✗Baseline serum potassium >5.0 mmol/L